Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology announced it will present topline data from the Phase 3 ECLIPSE 1 trial. This trial assesses the combination of elebsiran and tobevibart for chronic hepatitis delta. The presentation is scheduled for the AASLD The Liver Meeting 2026 in Denver, CO, from November 5-9, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Vir Biotechnology will present pivotal Phase 3 data.
  • The trial evaluates a combination treatment for hepatitis delta.
  • Presentation at a major conference enhances visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Cash runway
~13 mo
Medium dilution risk
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta in a late-breaking oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. Primary endpoint results of ECLIPSE 1: A randomized open-label Phase 3 study evaluatin

Frequently Asked Questions

What is the ECLIPSE 1 trial about?

The ECLIPSE 1 trial evaluates elebsiran and tobevibart for chronic hepatitis delta.

When will the ECLIPSE 1 data be presented?

The data will be presented at AASLD 2026 from November 5-9, 2026.

Where is the AASLD The Liver Meeting 2026 held?

The meeting will take place in Denver, Colorado.

What type of study is ECLIPSE 1?

ECLIPSE 1 is a randomized open-label Phase 3 study.

ShareAdd on Google
Tags: VIR Vir Biotechnology ECLIPSE 1 elebsiran tobevibart hepatitis delta
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$455M liquidity · $35M/mo burn
~13 mo
Medium dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →